Drugs / BB-12

Trials 1 · a red edge is where a trial was stopped

2020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 0 NCT03755765 Jul 2019 → Jan 2020 diarrheal disease Georgetown University Completed No outcome recorded
Also used as a comparator or background therapy in 3 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 01 trial
Phase 0 NCT04414722 Comparator Jan 2021 → May 2023 diarrheal disease Georgetown University Completed No outcome recorded
Phase 11 trial
Phase 1 NCT01652287 Comparator Feb 2013 → Jul 2014 Georgetown University Completed No outcome recorded
Phase 41 trial
Phase 4 NCT07296718 Comparator May → Nov 2023 neonatal sepsis, perinatal necrotizing enterocolitis Madiha, MPhil Completed No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as BB-12 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04414722
2

NCT03755765

NCT01652287

Known as Bifidobacterium animalis ssp. lactis “One of the most commonly used probiotics is Bifidobacterium animalis ssp. lactis (BB-12).” NCT01652287
Known as Bifidobacterium animalis subsp. lactis Bifidobacterium animalis subsp. lactis (B. lactis) strain BB-12 (BB-12) probiotic supplemented yogurt, 4 ounces taken orally for 10 days” NCT01652287
Known as Bifidobacterium animalis subsp. lactis BB-12 “The probiotic strain being studied, Bifidobacterium animalis subsp. lactis BB-12 (BB-12), has been shown to ameliorate a variety of gastrointestinal disease states and is known...” NCT03755765
1

“Bifidobacterium animalis subsp. lactis, BB-12” NCT04414722

Known as Bifidobacterium BB-12 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07296718